Additional file 17 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups
Analysis of RNA-seq gene expression signatures in CUTLL3 ETP-ALL cells following treatment with Vehicle or Pitavastatin for 48 hours RNA-seq from CUTLL3 cells treated with Vehicle or Pitavastatin for
Homo sapiens K562 treated with Panobinostat for 48 hours For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Dat
Aberrant splicing is an important cause of cancer, and the production of noncanonical, cancer-specific, mRNA transcripts associate with transformation. Studies have focused on characterizing the effec
The goal of this study is to compare single cell transcriptome of in vivo AML cells profiling before treatment and after venetoclax and cytarabine in single agent or after the duplet. This study uncov
Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system ac